Abstract
Ulcerative colitis (UC), a chronic, relapsing, remitting disease of the colon and rectum, is characterized by inflammatory ulceration of the mucosa. Current UC therapy relies on controlling acute episodes and preventing relapse. To predict modifications in the natural course of UC, mucosal healing (MH) has emerged as a major treatment goal. Endoscopic evaluation is considered the gold standard for assessing MH, which can be achieved by conventional drugs and biologics in many, but not all, patients. Consequently, interest is focusing on the development of new substances for UC therapy, and new oral agents are in the pipeline. This review will focus on the ability of newly developed oral drugs to induce and maintain MH in UC patients.
Keywords:
Mucosal healing; New oral treatments; Ozanimod; Peficitinib; Tofacitinib; Ulcerative colitis.
MeSH terms
-
Administration, Oral
-
Colitis, Ulcerative / diagnostic imaging
-
Colitis, Ulcerative / drug therapy*
-
Colitis, Ulcerative / immunology
-
Colitis, Ulcerative / pathology
-
Colon / diagnostic imaging
-
Colon / drug effects*
-
Colon / immunology
-
Colon / pathology
-
Colonoscopy
-
Gastrointestinal Agents / pharmacology
-
Gastrointestinal Agents / therapeutic use*
-
Humans
-
Integrin alpha4 / antagonists & inhibitors
-
Integrin alpha4 / immunology
-
Intestinal Mucosa / diagnostic imaging
-
Intestinal Mucosa / drug effects*
-
Intestinal Mucosa / immunology
-
Intestinal Mucosa / pathology
-
Janus Kinase Inhibitors / pharmacology
-
Janus Kinase Inhibitors / therapeutic use
-
Phosphatidylcholines / pharmacology
-
Phosphatidylcholines / therapeutic use
-
Receptors, Lysosphingolipid / antagonists & inhibitors
-
Receptors, Lysosphingolipid / immunology
-
Severity of Illness Index
-
Treatment Outcome
-
Wound Healing / drug effects
Substances
-
Gastrointestinal Agents
-
Janus Kinase Inhibitors
-
Phosphatidylcholines
-
Receptors, Lysosphingolipid
-
Integrin alpha4